AtriCure (ATRC) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $52.96 -0.13%
Revenue Growth %: +12.6%
Financial Fact:
Research and development expenses: 8.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +12.6%
Financial Fact:
Research and development expenses: 8.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $136.1 million versus the consensus estimate of $130.17 million.
GUIDANCE:
AtriCure sees FY2025 EPS of ($0.39)-($0.34), versus the consensus of ($0.51). AtriCure sees FY2025 revenue of $527-533 million, versus the consensus of $523 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
- Vistra prices $1.5B junior subordinated notes offering due 2057
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
